Seeking Alpha

Amarin (AMRN -6.4%) trades lower on negative comments out of Summer Street this morning, saying...

Amarin (AMRN -6.4%) trades lower on negative comments out of Summer Street this morning, saying that Vascepa might not be as key as previously thought. The firm notes that a member of AMRN's steering committee presented at a primary care conference last week, and said there was no reason to give Vascepa to patients with triglycerides <500 mg/dL until the outcome of current trials are completed, and, even if approval is granted early, sales are likely to disappoint.
Comments (8)
  • sharinky
    , contributor
    Comments (147) | Send Message
     
    This steering committee person was quoted as if they were an insider and could speak for the company. This insider did not say even if approval is granted early, sales are likely to disappoint. That was a quote from Summer Street an analyst firm who has been representing the short thesis for AMRN for quite some time.
    28 May 2013, 01:16 PM Reply Like
  • KillinMe
    , contributor
    Comments (37) | Send Message
     
    FUD, FUD, FUD... Can nobody see through this completely transparent game? Who takes any one of these "analyst firms" seriously? They're in it for the money just like anyone else. And you can bet they just made a ton of cash shorting AMRN stock off of this "comment".
    28 May 2013, 01:46 PM Reply Like
  • KillinMe
    , contributor
    Comments (37) | Send Message
     
    Anyone reading this do your own due diligence!! Research the science behind Vascepa. All the proof you need is right there as clear as day. For the love of God, don't blindly follow the words of a securities analyst. By the way, Omthera's hasn't even come close to even applying for FDA approval for their drug. So, it won't even be on the market for years, if it even gets there. Vascepa is ALREADY FOR SALE and by the time OMTH's baby gets going, Amarin probably won't even exist as it will have been bought out years before. At this point, this "story" is completely immaterial.
    28 May 2013, 01:50 PM Reply Like
  • nandito2010
    , contributor
    Comments (2) | Send Message
     
    What a mess .!!
    28 May 2013, 02:10 PM Reply Like
  • ralphey
    , contributor
    Comments (323) | Send Message
     
    Yea management that knows what they are doing could be useful at this point of the game
    28 May 2013, 02:39 PM Reply Like
  • Iamstockgeniusjustaskme
    , contributor
    Comments (248) | Send Message
     
    The thing that disturbs me here is why did AZN pass on us and buy an nonapproved FDA drug? I think the answer is quite telling (don't know the answer), but would love to know.

     

    Was Joey asking to much? As we have an approved drug, to me this is bad for Amarin overall. I remember Joe indicating he wouldn't take less than 30.00, and I often scratched my head as to why that was as that seemed overpriced.

     

    What is interesting is many will tell me I am nuts etc., please refer to the stock performance in the last six months. WS concurs that Amarin can't be successful without BP. If Joey can't understand this and sell at a market price instead of an exagerated price (if that is what he is doing) Joey needs to leave.
    28 May 2013, 04:41 PM Reply Like
  • Samuel-
    , contributor
    Comments (103) | Send Message
     
    Could Amrain actually win in the end, with all the haters out there?

     

    And why would they buy Omthera and not Amarin?
    28 May 2013, 04:43 PM Reply Like
  • Iamstockgeniusjustaskme
    , contributor
    Comments (248) | Send Message
     
    Additonally, Joey isn't going anywhere in my view because the lack of number of people on the board of directors.

     

    Many online are saying that the company is sold just waiting on NCE, well that could be announced could it not? Secondly, in my view do you imagine the lawsuits if shareholders that sold at losses find out the company was sold months ago but was waiting on a catalyst?
    28 May 2013, 04:44 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|